$QTTB

Q32 Bio Inc. (QTTB) appointed José Trevejo, M.D., Ph.D., as Chief Medical Officer and Ellie Hershberger, Pharm.D., as Chief Development Officer. The company is advancing Bempikibart into late-stage development for alopecia areata, with a registration-directed program planned for 2027. Bempikibart showed promising results in early trials, including hair regrowth and a well-tolerated safety profile. QTTB's stock is currently trading at $11.14, up 0.39%.

Apple (AAPL), Q32 Bio (QTTB), and CSX Corp. (CSX) reached 52-week highs. AAPL rose 0.6% to $323.45; Citi raised its target to $365. QTTB surged 90% after positive clinical data; Wells Fargo upgraded it to 'Overweight' with a $66 target. CSX gained 0.4% to $49.90; Raymond James lifted its target to $56. Year-to-date gains: AAPL +16%, CSX +36%, QTTB +543%.

Morrison Jodie Pope (CEO) sold 9,845 shares of Q32 Bio Inc. (FIXX) at $16.56 ($0.16M total) on 2026-08-25.

Analysts made several ratings changes: UBS upgraded Celestica to Buy with a $430 target, citing AI-driven demand. Citi initiated Reformation as Buy with a $20 target. Morgan Stanley initiated Jersey Mike's and ArcelorMittal as Overweight. Baird upgraded Darden to Outperform and downgraded Chipotle to Neutral. Other notable moves include upgrades for Suzano, Ionic Digital, and Fortune Brands, while Canada Goose was downgraded.

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Results of Operations and Financial Condition. Q32 Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update -- Reported positive bempikibart 36-week topline results from Part B of SIGNAL-AA clinical trial; additional details from 36-week results and initial findings from 52-week results to be presented

Q32 Bio Inc. (QTTB) disclosed in a Schedule 13G/A that Opaleye, L.P., Opaleye Management Inc., and James Silverman beneficially own 931,000 shares of its common stock, or 5.49%, based on 16,956,415 shares outstanding as of May 1, 2026. The filing attributes shared voting and dispositive power to the group and includes a beneficial-ownership disclaimer.

Q32 Bio Inc. (QTTB) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-1.1 2 d150730dex11.htm EX-1.1 EX-1.1 Exhibit 1.1 Q32 BIO INC. 6,027,399 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE PRE-FUNDED WARRANTS TO PURCHASE UP TO 4,931,506 SHARES OF COMMON STOCK, $0.0001 PAR VALUE PER SHARE UNDERWRITING AGREEMENT July 14, 2026 July 14, 2026 Mo

Q32 Bio (NASDAQ:QTTB) fell after announcing a $200M offering. It plans to sell 6,027,399 common shares at $18.25 and pre-funded warrants for 4,931,506 shares at $18.2499, with a $0.0001 exercise price. Underwriters may buy 1,643,835 more shares. Net proceeds fund working capital and bempikibart Phase 2 alopecia areata trials. Analysts expect Aug. 5 earnings.

Q32 Bio shares (QTTB) rose 90.72% after the company reported Phase 2a results for bempikibart in severe alopecia areata. The trial met its primary efficacy goal, with patients showing a 35% average reduction in scalp hair loss severity over 36 weeks, and no serious treatment-related adverse events. The stock later fell about 7% after a $200M offering; Oppenheimer raised its price target to $40.

Biotech gainers highlighted Q32 Bio (QTTB), up 90.7% to $21.38 after positive Phase 2 SIGNAL-AA results for bempikibart in alopecia areata, and it launched a $200M underwritten stock offering. Agenus (AGEN) rose 82.7% to $6.12 on a planned ~$85M private placement for BOT+BAL Phase 3 ROBBIN1. Other movers: ACTU, GALT, AMWL, SI.